Penumbra (PEN)
(Delayed Data from NYSE)
$233.30 USD
+4.43 (1.94%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$233.30 USD
+4.43 (1.94%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
Zacks News
Here's Why You Should Retain Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Bruker Corporation (BRKR) based on the strong performances of CALID and BioSpin Group and its raised 2023 outlook.
Boston Scientific (BSX) Gains From Acquisitions, New Launches
by Zacks Equity Research
Boston Scientific (BSX) remains excited about 2023 performance and expects to continue to outpace its peers within the EMEA market.
Abbott (ABT) Unveils Late-Breaking Data on Leadless Pacemaker
by Zacks Equity Research
Abbott (ABT) study analyzes primary safety and efficacy endpoints in the first 300 people enrolled across 55 centers in the United States, Canada and Europe.
Medtronic's (MDT) EV ICD Pivotal Study Shows Favorable Outcome
by Zacks Equity Research
Medtronic (MDT) announces that the findings of the EV ICD Pivotal Study reinforce device safety and effectiveness.
Here's Why You Should Retain Chemed (CHE) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed (CHE) on the strong performance of the VITAS Healthcare and Roto-Rooter segments.
Exact Sciences (EXAS) Gains From New Buyouts Amid High Costs
by Zacks Equity Research
Following the acquisitions of Paradigm and Ashion, Exact Sciences (EXAS) is now offering therapy selection tests for patients with advanced cancer.
Here's Why You Should Retain Insulet (PODD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Insulet (PODD) on the robust performance of Omnipod 5.
Zacks.com featured highlights Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and AeroVironment have been highlighted in this Screen of The Week article.
Thermo Fisher (TMO) Gets FDA Clearance for Its Immunoassays
by Zacks Equity Research
Thermo Fisher (TMO) announces the FDA clearance of its blood-based biomarkers used in the determination of risk assessment and clinical management of preeclampsia with severe features.
Buy These 4 Low-Beta Stocks to Sail Through Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and AeroVironment (AVAV) are poised to gain.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
QIAGEN (QGEN) is likely to benefit from high organic growth across its non-COVID-19 product group and portfolio advancements, reflecting a positive share price movement.
Should iShares Morningstar Small-Cap Growth ETF (ISCG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ISCG
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
by Zacks Equity Research
Myriad Genetics (MYGN) is likely to benefit from testing volumes across product segments and the latest partnerships, reflecting a positive share price movement.
Illumina (ILMN) Progresses in Pathogen Genomic Technologies
by Zacks Equity Research
Illumina's (ILMN) genomic surveillance solutions enable better pathogen preparedness and response.
Hologic (HOLX) Announces Collaboration With NFL CB Kelee Ringo
by Zacks Equity Research
Hologic (HOLX) and Eagles' CB, Kelee Ringo, come together to highlight the importance of annual mammograms and other routine health screenings.
Here's Why You Should Retain Charles River (CRL) Stock Now
by Zacks Equity Research
Charles River's (CRL) share price is likely to grow, backed by strategic acquisitions and the DSA segment's strength.
LabCorp (LH) Base Business Growth Strong, Margin Pressure Stays
by Zacks Equity Research
LabCorp (LH) is progressing well with its planned spin-off of the Clinical Development business, which is expected to be completed in mid-2023.
Here's Why Investors Should Retain Henry Schein (HSIC) for Now
by Zacks Equity Research
Henry Schein (HSIC) is expected to witness a favorable share price movement, led by optimism surrounding the performance of the dental business and strategic buyouts.
Integra (IART) Builds Advanced R&D Facility in New Jersey
by Zacks Equity Research
Integra (IART) opens the Dr. Richard E. Caruso Center of Innovation and Learning in New Jersey.
Syneos Health (SYNH) Announces a $7.1 Billion Merger Agreement
by Zacks Equity Research
Syneos Health (SYNH) is set to become private company following a $7.1 billion merger deal to be acquired by a private investment consortium.
Walgreens Boots (WBA) New Alliances Aid Growth, Cost Woe Stays
by Zacks Equity Research
Intensifying competition in the U.S. pharmacy retail drugstore market compels Walgreens Boots (WBA) to diversify its product offerings through new partnerships.
Penumbra (PEN) Hits 52-Week High: What's Driving the Rise?
by Zacks Equity Research
Penumbra (PEN) outperforms the industry and the S&P 500, backed by investors' optimism about the recently released first-quarter 2023 results.
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing
by Zacks Equity Research
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
Zacks.com featured highlights include Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk
by Zacks Equity Research
Penumbra, Lamb Weston, Transportadora de Gas del Sur and Novo Nordisk are part of the Zacks Screen of the Week article.
Buy These 4 Low-Beta Stocks to Endure Market Volatility
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. Penumbra (PEN), Lamb Weston (LW), Transportadora (TGS) and Novo Nordisk (NVO) are poised to gain.